Blue Jet Healthcare Reports Strong Q2 FY2027 Growth

Revenue rose to Rs 375.74 crore; Profit After Tax stands at Rs 102.52 crore.

Reader Takeaway: Robust top-line growth driven by core segments; QIP liquidity provides a clear pathway for future capital deployment.

What just happened

Blue Jet Healthcare has released its financial results for the quarter and half-year ended September 30, 2026. The company reported a significant jump in performance, with quarterly revenue reaching Rs 375.74 crore compared to Rs 165.48 crore in the corresponding quarter of the previous year. Net profit followed suit, rising to Rs 102.52 crore from Rs 52.14 crore year-over-year. The results have been verified with an unmodified conclusion by auditors KKC & Associates LLP.

The QIP Milestone

A major highlight for the quarter was the successful completion of a Qualified Institutional Placement (QIP). The company issued 1.58 crore equity shares at a price of Rs 506 per share, successfully raising Rs 800 crore. This infusion of capital is expected to provide the firm with substantial liquidity to fuel its operational and expansion requirements.

Business and Operational Context

Blue Jet Healthcare continues to function as a single-segment entity, specializing in Artificial Sweeteners, Contrast Media Intermediates, Pharma Intermediates, and APIs. As of the end of the second quarter, the company operates without any subsidiaries, associates, or joint ventures, keeping its financial structure straightforward for investors to track.

What to track next

Investors should look for management guidance regarding the allocation of the Rs 800 crore raised through the QIP. Capital expenditure plans or potential debt reduction strategies utilizing these proceeds will be the primary indicators of the company's long-term growth trajectory.